DE69009778T2 - Verwendung von selektiven gaba-b-agonisten als antitussiva. - Google Patents

Verwendung von selektiven gaba-b-agonisten als antitussiva.

Info

Publication number
DE69009778T2
DE69009778T2 DE69009778T DE69009778T DE69009778T2 DE 69009778 T2 DE69009778 T2 DE 69009778T2 DE 69009778 T DE69009778 T DE 69009778T DE 69009778 T DE69009778 T DE 69009778T DE 69009778 T2 DE69009778 T2 DE 69009778T2
Authority
DE
Germany
Prior art keywords
antitussiva
agonists
selective gaba
gaba
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69009778T
Other languages
English (en)
Other versions
DE69009778D1 (de
Inventor
William Kreutner
Donald Bolser
Richard Chapman
Sultan Aziz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE69009778D1 publication Critical patent/DE69009778D1/de
Publication of DE69009778T2 publication Critical patent/DE69009778T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69009778T 1989-12-20 1990-12-18 Verwendung von selektiven gaba-b-agonisten als antitussiva. Expired - Fee Related DE69009778T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/454,786 US5006560A (en) 1989-12-20 1989-12-20 Use of GABA-B selective agonists as anti-tussive agents
PCT/US1990/007290 WO1991008740A1 (en) 1989-12-20 1990-12-18 The use of gaba-b selective agonists as anti-tussive agents

Publications (2)

Publication Number Publication Date
DE69009778D1 DE69009778D1 (de) 1994-07-14
DE69009778T2 true DE69009778T2 (de) 1994-09-22

Family

ID=23806078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69009778T Expired - Fee Related DE69009778T2 (de) 1989-12-20 1990-12-18 Verwendung von selektiven gaba-b-agonisten als antitussiva.

Country Status (14)

Country Link
US (1) US5006560A (de)
EP (1) EP0506853B1 (de)
JP (1) JPH06102630B2 (de)
KR (1) KR950007208B1 (de)
AT (1) ATE106725T1 (de)
AU (1) AU642969B2 (de)
CA (1) CA2071981C (de)
DE (1) DE69009778T2 (de)
DK (1) DK0506853T3 (de)
ES (1) ES2055587T3 (de)
FI (1) FI922798A0 (de)
HU (1) HU212271B (de)
OA (1) OA09702A (de)
WO (1) WO1991008740A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231106A (en) * 1988-05-18 1993-07-27 Novo Nordisk A/S Azacyclic carboxylic acid derivatives and their preparation and use
US5214054A (en) * 1988-05-18 1993-05-25 Novo Nordisk A/S Azacyclic carboxylic acid derivatives and their preparation and use
US5229404A (en) * 1988-05-18 1993-07-20 Novo Nordisk A/S Azacyclic carboxylic acid derivatives and their preparation and use
DK588189D0 (da) * 1989-11-22 1989-11-22 Novo Nordisk As Nye heterocykliske carboxylsyrer
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
FR2662354B1 (fr) * 1990-05-23 1994-10-07 Adir Utilisation du baclofene pour l'obtention de medicaments destines au traitement de l'angine de poitrine.
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
US6194460B1 (en) * 1995-05-31 2001-02-27 Montefiore Medical Center Composition for treating cough induced by angiotensin converting enzyme inhibitors
US6121290A (en) * 1996-05-24 2000-09-19 Smithkline Beecham Corporation Use of GABA uptake inhibitors as anti-tussive agents
PT1077692E (pt) * 1998-05-15 2004-12-31 Warner Lambert Co Preparacoes farmaceuticas estabilizadas de derivados do acido aminobutirico e processos para a sua preparacao
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
US7109239B2 (en) * 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (de) 2003-08-20 2011-08-10 XenoPort, Inc. Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2117517B1 (de) * 2007-01-11 2011-06-01 XenoPort, Inc. Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
WO2009061934A1 (en) * 2007-11-06 2009-05-14 Xenoport, Inc. Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain
TWI369202B (en) * 2008-01-25 2012-08-01 Xenoport Inc Enantiomerically resolving acyloxyalkyl thiocarbonates used in synthesizing acyloxyalkyl carbamate prodrugs
EP2250148B1 (de) 2008-01-25 2016-08-17 XenoPort, Inc. Kristalline form von kalziumsalzen von (3s)-aminomethyl-5-methylhexansäuren und anwendungsverfahren
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
CA2753057C (en) 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
EP2419401A2 (de) * 2009-04-17 2012-02-22 XenoPort, Inc. Gamma-aminobuttersäurederivate als gabab-rezeptorliganden
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) * 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren

Also Published As

Publication number Publication date
EP0506853A1 (de) 1992-10-07
FI922798A (fi) 1992-06-17
HU9202077D0 (en) 1992-09-28
DE69009778D1 (de) 1994-07-14
JPH05504764A (ja) 1993-07-22
US5006560A (en) 1991-04-09
WO1991008740A1 (en) 1991-06-27
HUT61194A (en) 1992-12-28
KR950007208B1 (ko) 1995-07-04
AU642969B2 (en) 1993-11-04
KR920703043A (ko) 1992-12-17
HU212271B (en) 1996-04-29
ATE106725T1 (de) 1994-06-15
CA2071981C (en) 2002-06-25
ES2055587T3 (es) 1994-08-16
CA2071981A1 (en) 1991-06-21
AU7174591A (en) 1991-07-18
DK0506853T3 (da) 1994-08-01
EP0506853B1 (de) 1994-06-08
JPH06102630B2 (ja) 1994-12-14
OA09702A (en) 1993-08-30
FI922798A0 (fi) 1992-06-17

Similar Documents

Publication Publication Date Title
ATE106725T1 (de) Verwendung von selektiven gaba-b-agonisten als antitussiva.
ES2013226T3 (es) Una composicion que genera luz al activarse y su metodo de preparacion.
BR8505386A (pt) Revelador para a revelacao de uma camada de reproducao exposta a luz,que opera negativamente,processo para a preparacao de um molde de impressao,e aplicacao do dito revelador
FR2535058B1 (fr) Dispositif pour la detection et la quantification d'agglutinats
PT82974B (pt) Processo de sulfatacao de glicosamnoglicanos e de composicoes farmaceuticas que os contem
BR8801120A (pt) Composicao que e um supercondutor eletrico e processo para sua preparacao
ES2097802T3 (es) Solucion tampon de histidina para dialisis peritoneal.
ATE164486T1 (de) Verfahren zur behandlung von schnittblumen
ATE151533T1 (de) Musteranalyse durch kapillare elektrophorese
ES2074571T3 (es) Metodo para la deteccion de una substancia utilizando quimioluminiscencia.
IT8822338A0 (it) Procedimento e dispositivo per la misurazione dei valori di densita'ottica di un originale da riprodurre.
ATE110855T1 (de) Fingerabdruck-reagenz.
SE8304278L (sv) Forfarande for behandling av anvend, radioaktiv, organisk jonbytarmassa
EP0351513A3 (de) Fleckenabweisende Zusammensetzung für synthetische Fasern und Verfahren zur Verwendung
Trifaró et al. Anti-myosin stains chromaffin cells
BR8407181A (pt) Processo para compensar o erro de truncamento em um sinal amostrado e dispositivo para executar o processo
DK163988A (da) Sulfonerede 2-(2'-hydroxyaryl)-2h-benzotriazoler
EA200000140A1 (ru) Способ лечения диабета тиазолидиндионом, средством, усиливающим секрецию инсулина, и ингибитором альфа-глюкозидазы
PT90696A (pt) Processo de preparacao de novos compostos tri-iodobenzenicos nao ionicos e de produtos de contraste que os contem
ES2052493T3 (es) Utilizacion de inhibidores de girasa para la descontaminacion de cultivos celulares infectados con micoplasma.
DE59006159D1 (de) Verwendung von macrolactonen als antiallergica.
PT94011A (pt) Processo para a preparacao de 8 alfa- acilamino-ergolinas e de composicoes farmaceuticas que as contem
SE8500199D0 (sv) Forfarande for snabb bestemning av blodsenkan i venblod
SU648228A1 (ru) Способ получени эритроцитарных диагностикумов
ATE102038T1 (de) Eliminierung von aktivierten lymphozyten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee